{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:41:12Z","timestamp":1794613272216,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hanarth Foundation","id":[{"id":"https:\/\/ror.org\/05nk01292","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009709","name":"Stichting De Weijerhorst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009709","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of endometrial cancer is rising, and current diagnostics often require invasive biopsy procedures. Urine may offer an alternative sample type, which is easily accessible and allows repetitive self-sampling at home. Here, we set out to investigate the feasibility of endometrial cancer detection in urine using DNA methylation analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Urine samples of endometrial cancer patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200942) and healthy controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946) were separated into three fractions (full void urine, urine sediment, and urine supernatant) and tested for three DNA methylation markers (\n                      <jats:italic>GHSR<\/jats:italic>\n                      ,\n                      <jats:italic>SST<\/jats:italic>\n                      ,\n                      <jats:italic>ZIC1<\/jats:italic>\n                      ). Strong to very strong correlations (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.77\u20130.92) were found amongst the different urine fractions. All DNA methylation markers showed increased methylation levels in patients as compared to controls, in all urine fractions. The highest diagnostic potential for endometrial cancer detection in urine was found in full void urine, with area under the receiver operating characteristic curve values ranging from 0.86 to 0.95.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This feasibility study demonstrates, for the first time, that DNA methylation analysis in urine could provide a non-invasive alternative for the detection of endometrial cancer. Further investigation is warranted to validate its clinical usefulness. Potential applications of this diagnostic approach include the screening of asymptomatic women, triaging women with postmenopausal bleeding symptoms, and monitoring women with increased endometrial cancer risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-020-00958-7","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T09:03:03Z","timestamp":1604394183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Non-invasive detection of endometrial cancer by DNA methylation analysis in urine"],"prefix":"10.1186","volume":"12","author":[{"given":"Rianne","family":"van den Helder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit M. M.","family":"Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke E.","family":"van Trommel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina P.","family":"van Splunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantijne H.","family":"Mom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenneke C.","family":"Kasius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike C. G.","family":"Bleeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-9839","authenticated-orcid":false,"given":"Renske D. M.","family":"Steenbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"issue":"1","key":"958_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"958_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1055-9965.EPI-18-0264","volume":"27","author":"AS Felix","year":"2018","unstructured":"Felix AS, Brinton LA. Cancer progress and priorities: uterine cancer. Cancer Epidemiol Biomark Prev. 2018;27(9):985\u201394.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"958_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"10023","key":"958_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","volume":"387","author":"P Morice","year":"2016","unstructured":"Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094\u2013108.","journal-title":"Lancet"},{"issue":"35","key":"958_CR5","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1200\/JCO.2016.69.4638","volume":"34","author":"MA Onstad","year":"2016","unstructured":"Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225\u201330.","journal-title":"J Clin Oncol"},{"issue":"12","key":"958_CR6","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1002\/ijc.32514","volume":"145","author":"L Costas","year":"2019","unstructured":"Costas L, Frias-Gomez J, Guardiola M, Benavente Y, Pineda M, Pavon MA, et al. New perspectives on screening and early detection of endometrial cancer. Int J Cancer. 2019;145(12):3194\u2013206.","journal-title":"Int J Cancer"},{"key":"958_CR7","doi-asserted-by":"crossref","unstructured":"Crosbie E, Morrison J. The emerging epidemic of endometrial cancer: Time to take action. Cochrane Database Syst Rev 2014(12):ED000095.","DOI":"10.1002\/14651858.ED000095"},{"key":"958_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","volume":"70","author":"M Kulis","year":"2010","unstructured":"Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27\u201356.","journal-title":"Adv Genet"},{"issue":"1","key":"958_CR9","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.3802\/jgo.2018.29.e17","volume":"29","author":"CC Chang","year":"2018","unstructured":"Chang CC, Wang HC, Liao YP, Chen YC, Weng YC, Yu MH, et al. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings. J Gynecol Oncol. 2018;29(1):e17.","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"958_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/jclinpath-2014-202616","volume":"67","author":"LM De Strooper","year":"2014","unstructured":"De Strooper LM, van Zummeren M, Steenbergen RD, Bleeker MC, Hesselink AT, Wisman GB, et al. CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol. 2014;67(12):1067\u201371.","journal-title":"J Clin Pathol"},{"issue":"1","key":"958_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1078-0432.CCR-16-0863","volume":"23","author":"RL Huang","year":"2017","unstructured":"Huang RL, Su PH, Liao YP, Wu TI, Hsu YT, Lin WY, et al. Integrated epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings. Clin Cancer Res. 2017;23(1):263\u201372.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"958_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13148-019-0765-3","volume":"11","author":"PL Liew","year":"2019","unstructured":"Liew PL, Huang RL, Wu TI, Liao CC, Chen CW, Su PH, et al. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. Clin Epigenet. 2019;11(1):170.","journal-title":"Clin Epigenet"},{"issue":"8","key":"958_CR13","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.28843","volume":"135","author":"N Wentzensen","year":"2014","unstructured":"Wentzensen N, Bakkum-Gamez JN, Killian JK, Sampson J, Guido R, Glass A, et al. Discovery and validation of methylation markers for endometrial cancer. Int J Cancer. 2014;135(8):1860\u20138.","journal-title":"Int J Cancer"},{"issue":"6","key":"958_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1097\/IGC.0b013e3182959103","volume":"23","author":"K Doufekas","year":"2013","unstructured":"Doufekas K, Hadwin R, Kandimalla R, Jones A, Mould T, Crowe S, et al. GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. Int J Gynecol Cancer. 2013;23(6):1050\u20135.","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"958_CR15","doi-asserted-by":"publisher","first-page":"e1001551","DOI":"10.1371\/journal.pmed.1001551","volume":"10","author":"A Jones","year":"2013","unstructured":"Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, et al. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med. 2013;10(11):e1001551.","journal-title":"PLoS Med"},{"issue":"1","key":"958_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2015.01.552","volume":"137","author":"JN Bakkum-Gamez","year":"2015","unstructured":"Bakkum-Gamez JN, Wentzensen N, Maurer MJ, Hawthorne KM, Voss JS, Kroneman TN, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol. 2015;137(1):14\u201322.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"958_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ygyno.2019.11.028","volume":"156","author":"A Sangtani","year":"2020","unstructured":"Sangtani A, Wang C, Weaver A, Hoppman NL, Kerr SE, Abyzov A, et al. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. Gynecol Oncol. 2020;156(2):387\u201392.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"958_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41379-018-0158-8","volume":"32","author":"AM Bolivar","year":"2019","unstructured":"Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, Hu P, et al. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol. 2019;32(3):405\u201314.","journal-title":"Mod Pathol"},{"issue":"11","key":"958_CR19","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3390\/ijms20112657","volume":"20","author":"LK Larsen","year":"2019","unstructured":"Larsen LK, Lind GE, Guldberg P, Dahl C. DNA-methylation-based detection of urological cancer in urine: overview of biomarkers and considerations on biomarker design, source of DNA, and detection technologies. Int J Mol Sci. 2019;20(11):2657.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"958_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1208\/s12248-018-0220-y","volume":"20","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Moxley K, Ruskin R, Dhanasekaran DN, Zhao YD, Ramesh R. A Non-invasive liquid biopsy screening of urine-derived exosomes for miRNAs as biomarkers in endometrial cancer patients. AAPS J. 2018;20(5):82.","journal-title":"AAPS J"},{"issue":"4","key":"958_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s12253-015-9914-y","volume":"21","author":"L Zavesky","year":"2015","unstructured":"Zavesky L, Jandakova E, Turyna R, Langmeierova L, Weinberger V, Zaveska Drabkova L, et al. Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers: a pilot study. Pathol Oncol Res. 2015;21(4):1027\u201335.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"958_CR22","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1038\/s41598-019-39275-2","volume":"9","author":"BC Snoek","year":"2019","unstructured":"Snoek BC, Splunter APV, Bleeker MCG, Ruiten MCV, Heideman DAM, Rurup WF, et al. Cervical cancer detection by DNA methylation analysis in urine. Sci Rep. 2019;9(1):3088.","journal-title":"Sci Rep"},{"key":"958_CR23","doi-asserted-by":"publisher","first-page":"100193","DOI":"10.1016\/j.pvr.2020.100193","volume":"9","author":"R van den Helder","year":"2020","unstructured":"van den Helder R, van Trommel NE, van Splunter AP, Lissenberg-Witte BI, Bleeker MCG, Steenbergen RDM. Methylation analysis in urine fractions for optimal CIN3 and cervical cancer detection. Papillomavirus Res. 2020;9:100193.","journal-title":"Papillomavirus Res"},{"issue":"3","key":"958_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2217\/epi-2018-0094","volume":"11","author":"J Bosschieter","year":"2019","unstructured":"Bosschieter J, Nieuwenhuijzen JA, Hentschel A, van Splunter AP, Segerink LI, Vis AN, et al. A two-gene methylation signature for the diagnosis of bladder cancer in urine. Epigenomics. 2019;11(3):337\u201347.","journal-title":"Epigenomics"},{"issue":"4","key":"958_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/cancers12040859","volume":"12","author":"AE Hentschel","year":"2020","unstructured":"Hentschel AE, Nieuwenhuijzen JA, Bosschieter J, Splunter APV, Lissenberg-Witte BI, Voorn JPV, et al. Comparative analysis of urine fractions for optimal bladder cancer detection using DNA methylation markers. Cancers (Basel). 2020;12(4):859.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"958_CR26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1055-9965.EPI-11-0067","volume":"20","author":"W Chung","year":"2011","unstructured":"Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomark Prev. 2011;20(7):1483\u201391.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"958_CR27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/ijms21031117","volume":"21","author":"M Rose","year":"2020","unstructured":"Rose M, Bringezu S, Godfrey L, Fiedler D, Gaisa NT, Koch M, et al. ITIH5 and ECRG4 DNA methylation biomarker test (EI-BLA) for urine-based non-invasive detection of bladder cancer. Int J Mol Sci. 2020;21(3):1117.","journal-title":"Int J Mol Sci"},{"key":"958_CR28","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-19-2896","volume":"26","author":"B Liu","year":"2020","unstructured":"Liu B, Ricarte Filho J, Mallisetty A, Villani C, Kottorou A, Rodgers K, et al. Detection of promoter DNA methylation in urine and plasma aids the detection of non-small cell lung cancer. Clin Cancer Res. 2020;26:4339\u201348.","journal-title":"Clin Cancer Res"},{"key":"958_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13148-018-0524-x","volume":"10","author":"I Brikun","year":"2018","unstructured":"Brikun I, Nusskern D, Decatus A, Harvey E, Li L, Freije D. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA. Clin Epigenet. 2018;10:91.","journal-title":"Clin Epigenet"},{"key":"958_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-019-0137-x","volume":"8","author":"I Brikun","year":"2019","unstructured":"Brikun I, Nusskern D, Freije D. An expanded biomarker panel for the detection of prostate cancer from urine DNA. Exp Hematol Oncol. 2019;8:13.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"958_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13148-018-0564-2","volume":"10","author":"C Moreira-Barbosa","year":"2018","unstructured":"Moreira-Barbosa C, Barros-Silva D, Costa-Pinheiro P, Torres-Ferreira J, Constancio V, Freitas R, et al. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. Clin Epigenet. 2018;10(1):132.","journal-title":"Clin Epigenet"},{"issue":"4","key":"958_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.juro.2018.04.067","volume":"200","author":"LK Larsen","year":"2018","unstructured":"Larsen LK, Jakobsen JS, Abdul-Al A, Guldberg P. Noninvasive detection of high grade prostate cancer by DNA methylation analysis of urine cells captured by microfiltration. J Urol. 2018;200(4):749\u201357.","journal-title":"J Urol"},{"issue":"18","key":"958_CR33","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.2217\/epi-2020-0164","volume":"12","author":"RV den Helder","year":"2020","unstructured":"den Helder RV, Wever BM, van Trommel JA, Ket JC, Bleeker MC, Steenbergen RD, et al. DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review. Epigenomics. 2020;12(18):1661\u201372.","journal-title":"Epigenomics"},{"issue":"5","key":"958_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/15384101.2015.1006051","volume":"14","author":"P Jandaghi","year":"2015","unstructured":"Jandaghi P, Hoheisel JD, Riazalhosseini Y. GHSR hypermethylation: a promising pan-cancer marker. Cell Cycle. 2015;14(5):689\u201390.","journal-title":"Cell Cycle"},{"issue":"4","key":"958_CR35","doi-asserted-by":"publisher","first-page":"e0231058","DOI":"10.1371\/journal.pone.0231058","volume":"15","author":"E Augustus","year":"2020","unstructured":"Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of obtaining a high yield of cell-free DNA from urine. PLoS ONE. 2020;15(4):e0231058.","journal-title":"PLoS ONE"},{"issue":"8","key":"958_CR36","doi-asserted-by":"publisher","first-page":"e0200906","DOI":"10.1371\/journal.pone.0200906","volume":"13","author":"J Bosschieter","year":"2018","unstructured":"Bosschieter J, Bach S, Bijnsdorp IV, Segerink LI, Rurup WF, van Splunter AP, et al. A protocol for urine collection and storage prior to DNA methylation analysis. PLoS ONE. 2018;13(8):e0200906.","journal-title":"PLoS ONE"},{"issue":"2","key":"958_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2144\/btn-2019-0092","volume":"68","author":"M Webb","year":"2020","unstructured":"Webb M, Manley K, Olivan M, Guldvik I, Palczynska M, Hurst R, et al. Methodology for the at-home collection of urine samples for prostate cancer detection. Biotechniques. 2020;68(2):65\u201371.","journal-title":"Biotechniques"},{"key":"958_CR38","doi-asserted-by":"crossref","first-page":"638165","DOI":"10.1155\/2010\/638165","volume":"2010","author":"V Masciullo","year":"2010","unstructured":"Masciullo V, Amadio G, Lo Russo D, Raimondo I, Giordano A, Scambia G. Controversies in the management of endometrial cancer. Obstet Gynecol Int. 2010;2010:638165.","journal-title":"Obstet Gynecol Int"},{"issue":"5","key":"958_CR39","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1097\/IGC.0000000000000423","volume":"25","author":"CC Billingsley","year":"2015","unstructured":"Billingsley CC, Kenne KA, Cansino CD, Backes FJ, Cohn DE, O\u2019Malley DM, et al. The use of transvaginal ultrasound in type II endometrial cancer. Int J Gynecol Cancer. 2015;25(5):858\u201362.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"958_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ygyno.2005.09.042","volume":"101","author":"J Wang","year":"2006","unstructured":"Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol. 2006;101(1):120\u20135.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"958_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(10)70268-0","volume":"12","author":"I Jacobs","year":"2011","unstructured":"Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011;12(1):38\u201348.","journal-title":"Lancet Oncol"},{"issue":"6","key":"958_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5468\/ogs.2019.62.6.445","volume":"62","author":"YR Park","year":"2019","unstructured":"Park YR, Lee SW, Kim Y, Bae IY, Kim HK, Choe J, et al. Endometrial thickness cut-off value by transvaginal ultrasonography for screening of endometrial pathology in premenopausal and postmenopausal women. Obstet Gynecol Sci. 2019;62(6):445\u201353.","journal-title":"Obstet Gynecol Sci"},{"issue":"1","key":"958_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/AOG.0b013e3181e3e7e8","volume":"116","author":"A Timmermans","year":"2010","unstructured":"Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):160\u20137.","journal-title":"Obstet Gynecol"},{"key":"958_CR44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/IJWH.S172696","volume":"10","author":"A Aue-Aungkul","year":"2018","unstructured":"Aue-Aungkul A, Kleebkaow P, Kietpeerakool C. Incidence and risk factors for insufficient endometrial tissue from endometrial sampling. Int J Womens Health. 2018;10:453\u20137.","journal-title":"Int J Womens Health"},{"issue":"2","key":"958_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/GRF.0b013e3182185baa","volume":"54","author":"SN Lewin","year":"2011","unstructured":"Lewin SN. Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol. 2011;54(2):215\u20138.","journal-title":"Clin Obstet Gynecol"},{"issue":"14","key":"958_CR46","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1158\/1078-0432.CCR-16-2641","volume":"23","author":"W Verlaat","year":"2017","unstructured":"Verlaat W, Snijders PJF, Novianti PW, Wilting SM, De Strooper LMA, Trooskens G, et al. Genome-wide DNA methylation profiling reveals methylation markers associated with 3q gain for detection of cervical precancer and cancer. Clin Cancer Res. 2017;23(14):3813\u201322.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-020-00958-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T17:15:26Z","timestamp":1723828526000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-020-00958-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1186\/s13148-020-00958-7","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained by the Medical Ethical Committee of the VU University Medical Center for both the SOLUTION1 study (No. 2016.213) and the URIC biobank (No. 2017.112). Each participant gave written informed consent upon recruitment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RDMS has a minority share in Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}